The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SALCS 2022 | Challenges in developing CAR-T cells for liver cancer
Treatment options for liver cancer remain limited, with a handful of small molecule inhibitors and checkpoint inhibitors available for patients. Mitchell Ho, PhD, National Institutes of Health, Bethesda, MD, describes current barriers producing CAR-T cells for hepatocellular carcinoma. The extracellular matrix, tumor microenvironment and cirrhosis are challenges that need to be overcome for efficacious CAR-T cells in the liver. Dr Ho additionally highlights GPC3, a tumor-specific antigen, as well as bispecific antibodies, antibody drug conjugates and natural killer (NK) cell engagers. This interview took place at the 2022 San Antonio Liver Cancer Symposium (SALCS) in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
